News & Announcements
NIAID Awards Paragon Bioservices a Multiple Award IDIQ Contract valued up to $159M for Preclinical Drug Development Services
January 18, 2017
Baltimore, MD (USA), January 3 – Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to provide product development services for a variety of National Institute of Allergy and Infectious Diseases (NIAID) medical product development activities. The IDIQ mechanism will allow Paragon to compete within a contractor pool for task order awards up to $159 million.
Paragon Bioservices, a global leader in manufacturing and process development of biopharmaceuticals, is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years. (FedBizOpps notice). The award covers the development and introduction of new therapeutic products against a range of critical global infectious diseases. Under the contract, the company will develop manufacturing processes and analytical test methods and perform product characterization. “Paragon Bioservices considers this award to be a significant honor which reflects the expertise and dedication of every Paragon employee,” said President, CEO, and Board member Pete Buzy. “Paragon is very excited to be working closely with NIAID on preclinical drug development. Over the next decade, Paragon will play an integral role by advancing research and development in the global vaccine market and public health. As a leader in biotherapeutic development and Phase I/II cGMP manufacturing, Paragon is strategically aligned to provide exceptional service and quality. For the past 26 years Paragon has demonstrated commitment to our client’s and their corporate goals. We are certain we can carry on this tradition in the years to come.”
Click here to read the rest of the story